You are here

CHANTEST, INC.

Company Information
Address
14656 NEO PKY
CLEVELAND, OH -
United States



Information

UEI: N/A

# of Employees: N/A


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Optimizing the Action Potential of Stem Cell-derived Human Cardiomyocytes for Car

    Amount: $1,184,308.00

    DESCRIPTION (provided by applicant): Stem Cell-derived Human Cardiomyocytes (SC-hCMs) offer great potential for improving the accuracy of pre- clinical cardiac safety testing. We have characterized a ...

    SBIRPhase II2012Department of Health and Human Services National Institutes of Health
  2. Optimizing the Action Potential of Stem Cell-derived Human Cardiomyocytes for Car

    Amount: $149,275.00

    DESCRIPTION (provided by applicant): Stem Cell-derived Human Cardiomyocytes (SC-hCMs) offer great potential for improving the accuracy of pre-clinical cardiac safety screening. We have recently charac ...

    SBIRPhase I2010Department of Health and Human Services National Institutes of Health
  3. Development of a Complete Proarrhythmic Safety Profile for Drugs

    Amount: $149,322.00

    DESCRIPTION (provided by applicant): ChanTest's goal is to commercialize a comprehensive non-clinical proarrhythmic profile that will screen compounds through a battery of models that span from the mo ...

    SBIRPhase I2006Department of Health and Human Services National Institutes of Health
  4. New drugs for treatment of atrial fibrillation

    Amount: $0.00

    DESCRIPTION (provided by applicant): Atrial fibrillation (AF) is the most common cause of arrhythmias in the elderly; it has an incidence of more than 5 percent in people > 69 years of age. At present ...

    SBIRPhase I2003Department of Health and Human Services National Institutes of Health
  5. New drugs for treatment of atrial fibrillation

    Amount: $580,448.00

    DESCRIPTION (provided by applicant): Atrial fibrillation (AF) is the most common cause of arrhythmias in the elderly; it has an incidence of more than 5 percent in people > 69 years of age. At present ...

    SBIRPhase II2003Department of Health and Human Services National Institutes of Health
  6. New drugs for treatment of atrial fibrillation

    Amount: $99,924.00

    Atrial fibrillation (AF) is the commonest cardiac arrhythmia and in its chronic form affects more than two million patients in the USA. AF is associated with cardiac and non-cardiac diseases. About 10 ...

    SBIRPhase I2001Department of Health and Human Services National Institutes of Health
  7. NOVEL SIMPLE SCREEN FOR POTASSIUM CHANNELS

    Amount: $89,263.00

    N/A

    SBIRPhase I1998Department of Health and Human Services
US Flag An Official Website of the United States Government